N-methylglycine (Sarcosine) for Treatment of Major Depressive Disorder
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Remission rate
研究概览
简要总结
Major depressive disorder is a complex disease and most currently available antidepressants aiming at monoamine neurotransmission exhibit limited efficacy and cognitive effects. N-methyl-D-aspartate (NMDA), one subtype of glutamate receptors, plays an important role in learning and memory. N-methyl-D-aspartic acid (NMDA) enhancing agents, such as sarcosine (N-methylglycine), have been used as adjunctive therapy of schizophrenia. Sarcosine improved not only psychotic but also depressive symptoms in patients with schizophrenia. To confirm its antidepressant effect, the purpose of this study is to compare citalopram and sarcosine in efficacy for major depressive patients.
详细描述
Major depressive disorder is a complex disease and most currently available antidepressants aiming at monoamine neurotransmission exhibit limited efficacy and cognitive effects. Novel therapies via manipulating other neurotransmission (e.g. glutamate receptor) are being developed.
NMDA enhancing agents, such as sarcosine have been demonstrated to improve negative symptoms and depressive symptoms of schizophrenic patients. The purpose of this study is to compare citalopram and sarcosine in aspects of efficacy, safety in major depressive patients.
In the study, 40 major depressive patients are recruited into the 6-week trial and randomly assigned into the two groups (20-60 mg/d citalopram, or 500 - 1500 mg/d sarcosine) with a double-blind manner. Hamilton Depression Rating Scale(17-item), CGI(Clinical Global Impression), GAF(Global Assessment of Function)and side effects are evaluated every two weeks during the trial. The efficacies of two groups are compared.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18-55 years
- •Fulfilled the DSM-IV criteria of major depressive disorder
- •Had a 17-item Hamilton Rating Scale for Depression (HAMD-17)>or= 18
- •No DSM-IV diagnosis of substance abuse or dependence (including alcohol) within the past 6 months
- •Had been drug free for > 3 months
- •Physically healthy and had all laboratory parameters within normal limits.
- •Agree to participate in the study and provide informed consent
排除标准
- •Had history of epilepsy, head trauma or other major neurological or medical diseases
- •Had psychotic depression, bipolar I/II disorder, schizophrenia or any other psychotic disorder
- •Moderate-severe suicidal risks
- •Severe cognitive impairment
- •Female subjects who were pregnant, or at risk of pregnancy or lactation
- •Initiating or stopping formal psychotherapy within six weeks prior to enrollment
- •Had a history of poor response to SSRIs or previously received electroconvulsive therapy
- •Had a history of severe adverse reaction to SSRIs.
研究组 & 干预措施
sarcosine
sarcosine
干预措施: sarcosine (Drug)
citalopram
citalopram
干预措施: citalopram (Drug)
结局指标
主要结局
Remission rate
时间窗: week 0, 2,4, 6
17-item Hamilton Depression Rating Scale
时间窗: week 0, 2, 4, 6
score change
GAF(Global Assessment of Function)
时间窗: Week 0, 2, 4, 6
score changes
次要结局
- dropout rate(week 0, 2, 4, 6)
- CGI(clinical global impression)(week 0, 2, 4,6)
- Response Rate(Week 0, 2, 4, 6)
- Factors of 17-item Hamilton Depression Rating Scale(Week 0, 2, 4, 6)